Study of MRG003 with gemcitabine for advanced pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new drug called MRG003 combined with gemcitabine for people with advanced pancreatic cancer that has not responded to or stopped responding to first-line treatment. It aims to see if this combination can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced pancreatic cancer (locally advanced or spread to other parts of the body).
- Your cancer has progressed after or you could not tolerate your first treatment.
- You are able to perform daily activities with some help (ECOG score 0-2).
- You have adequate organ and bone marrow function.
- You are willing to provide a tumor tissue sample (either from a previous biopsy or a new one).
- You have not had gemcitabine as your first treatment and have not been treated with an ADC drug like MMAE.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, MR001, combined with chemotherapy for people whose pancreatic cancer has spread and no longer responds to their first treatment. It aims to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
This study tests a new drug (MRG004A) for advanced pancreatic cancer that has not responded to earlier treatments. The drug is given together with best supportive care (treatments to manage symptoms), and compared to a placebo (a dummy treatment) with best supportive care. The goal is to see if the new drug can slow down the cancer and help you live longer.
This trial tests a new targeted drug (LM-302) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that has progressed after initial treatment. The goal is to see if this combination can slow down or shrink the cancer.
This trial tests a combination of three medicines to see if they can slow down or shrink pancreatic cancer that has not responded to previous treatments or has come back. It might help if you are generally healthy and your cancer is advanced.
This trial tests a new drug, MRG006A, for people with advanced solid tumors, especially liver cancer. It aims to see if the drug is safe and effective by targeting a protein called GPC3 found on some cancer cells.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.